Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical has announced that its subsidiary Chongqing Carelife Pharmaceutical has obtained National Medical Products Administration approval for Sodium Thiosulfate Injection. The drug, classified as a Category 3 chemical and manufactured by Yaopharma, is indicated for the treatment of cyanide poisoning and various heavy metal poisonings, broadening the group’s emergency and toxicology treatment portfolio.
The approval strengthens Fosun Pharma’s position in critical care and antidote therapies, adding a new injectable product to its portfolio that targets acute poisoning scenarios often handled in hospital emergency departments. This regulatory milestone may enhance the subsidiary’s competitive standing in China’s hospital drug market and supports the group’s strategy of expanding high-value, specialized pharmaceuticals.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare group engaged in the research, development, manufacturing and distribution of pharmaceutical products. Through its subsidiaries, the company focuses on both innovative and generic drugs, serving hospital, emergency and broader medical markets in China and overseas.
Average Trading Volume: 2,904,222
Technical Sentiment Signal: Sell
Current Market Cap: HK$71.04B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.